Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis
Miriam Satler (non-author presenter)
0 views
0 downloads
Powered by
Discover more research and events on morressier.com